Gene Regulation Laboratories

Gene Regulation Laboratories (GRL) is a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for life-threatening viral infections and cancer. The company leverages a proprietary drug discovery platform focused on protease inhibition to create treatments that are effective against drug-resistant viral strains. GRL's research is anchored by the pioneering work of Dr. Hiroaki Mitsuya, who is renowned for his role in developing the first successful treatments for HIV/AIDS. Their current pipeline features promising candidates targeting the papain-like protease (PLpro) and main protease (Mpro) of SARS-CoV-2, as well as next-generation HIV-1 protease inhibitors. By focusing on highly conserved viral targets, GRL aims to provide robust therapeutic options for both current and emerging global health challenges.